Cargando…

DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers

Cancer immune evasion contributes to checkpoint immunotherapy failure in many patients with metastatic cancers. The embryonic transcription factor DUX4 was recently characterized as a suppressor of interferon-γ signaling and antigen presentation that is aberrantly expressed in a small subset of prim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pineda, Jose Mario Bello, Bradley, Robert K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369889/ https://www.ncbi.nlm.nih.gov/pubmed/37502871 http://dx.doi.org/10.1101/2023.07.10.548412

Ejemplares similares

Telomeres cooperate in zygotic genome activation by affecting DUX4/Dux transcription
por: Zhang, Xiaorui, et al.
Publicado: (2023)

Conserved roles for murine DUX and human DUX4 in activating cleavage stage genes and MERVL/HERVL retrotransposons
por: Hendrickson, Peter G., et al.
Publicado: (2017)

DUX Hunting—Clinical Features and Diagnostic Challenges Associated with DUX4-Rearranged Leukaemia
por: Rehn, Jacqueline A., et al.
Publicado: (2020)

Immunotherapy and Immune Evasion in Prostate Cancer
por: Thakur, Archana, et al.
Publicado: (2013)

Analysis of DUX4 Expression in Bone Marrow and Re-Discussion of DUX4 Function in the Health and Disease
por: Hangul, Ceren, et al.
Publicado: (2022)

Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4
por: Eidahl, Jocelyn O., et al.
Publicado: (2016)

Homologous Transcription Factors DUX4 and DUX4c Associate with Cytoplasmic Proteins during Muscle Differentiation
por: Ansseau, Eugénie, et al.
Publicado: (2016)

DUX4(HD2)-DNA(ERG) structure reveals new insight into DUX4-Responsive-Element
por: Dong, Xue, et al.
Publicado: (2018)

DNA-binding sequence specificity of DUX4
por: Zhang, Yu, et al.
Publicado: (2016)

Immune Evasion as the Main Challenge for Immunotherapy of Cancer
por: Zagozdzon, Radoslaw, et al.
Publicado: (2022)

Therapeutic Strategies Targeting DUX4 in FSHD
por: Le Gall, Laura, et al.
Publicado: (2020)

Human DUX4 and mouse Dux interact with STAT1 and broadly inhibit interferon-stimulated gene induction
por: Spens, Amy E, et al.
Publicado: (2023)

A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene
por: Leidenroth, Andreas, et al.
Publicado: (2010)

DUX4-Induced Histone Variants H3.X and H3.Y Mark DUX4 Target Genes for Expression
por: Resnick, Rebecca, et al.
Publicado: (2019)

Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcoma
por: Bosnakovski, Darko, et al.
Publicado: (2021)

CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy
por: Das, Sunny, et al.
Publicado: (2021)

Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy
por: Ganassi, Massimo, et al.
Publicado: (2022)

Structural basis of DUX4/IGH-driven transactivation
por: Dong, Xue, et al.
Publicado: (2018)

Functional domains of the FSHD-associated DUX4 protein
por: Mitsuhashi, Hiroaki, et al.
Publicado: (2018)

Conservation and innovation in the DUX4-family gene network
por: Whiddon, Jennifer L., et al.
Publicado: (2017)

DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Molecular and Phenotypic Changes in FLExDUX4 Mice
por: Murphy, Kelly, et al.
Publicado: (2023)

The transcription factor DUX4 orchestrates translational reprogramming by broadly suppressing translation efficiency and promoting expression of DUX4-induced mRNAs
por: Hamm, Danielle C., et al.
Publicado: (2023)

Synergistic effect of glutathione and IgG4 in immune evasion and the implication for cancer immunotherapy()
por: Zhang, Weifeng, et al.
Publicado: (2023)

Designed U7 snRNAs inhibit DUX4 expression and improve FSHD-associated outcomes in DUX4 overexpressing cells and FSHD patient myotubes
por: Rashnonejad, Afrooz, et al.
Publicado: (2020)

Extracellular Vesicles in Herpes Viral Spread and Immune Evasion
por: Bello-Morales, Raquel, et al.
Publicado: (2018)

Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
por: Qiu, Yingqi, et al.
Publicado: (2021)

A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy
por: Feng, Qing, et al.
Publicado: (2015)

TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
por: Chakravarthy, Ankur, et al.
Publicado: (2018)

The FSHD Atrophic Myotube Phenotype Is Caused by DUX4 Expression
por: Vanderplanck, Céline, et al.
Publicado: (2011)

Culture Conditions Affect Expression of DUX4 in FSHD Myoblasts
por: Pandey, Sachchida Nand, et al.
Publicado: (2015)

G-quadruplex ligands mediate downregulation of DUX4 expression
por: Ciszewski, Lukasz, et al.
Publicado: (2020)

DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2021)

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy
por: Zhan, Lei, et al.
Publicado: (2020)

An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy
por: Wang, Hui, et al.
Publicado: (2020)

CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy
por: Pourchet, Aldo, et al.
Publicado: (2016)

hrHPV E5 oncoprotein: immune evasion and related immunotherapies
por: de Freitas, Antonio Carlos, et al.
Publicado: (2017)

The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2021)

Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma
por: Evdokimova, Valentina, et al.
Publicado: (2022)

Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy
por: Bou-Dargham, Mayassa J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q19r3es43clpgnha3hsuo4s981